Currently out of the existing stock ratings of Tiago Fauth, 105 are a BUY (71.43%), 37 are a HOLD (25.17%), 5 are a SELL (3.4%).

Tiago Fauth

Work Performance Price Targets & Ratings Chart

Analyst Tiago Fauth, currently employed at WELLS FARGO, carries an average stock price target met ratio of 42.96% that have a potential upside of 20.98% achieved within 113 days. Previously, Tiago Fauth worked at CREDIT SUISSE.

Tiago Fauth’s has documented 293 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RARE, Ultragenyx at 20-Dec-2024.

Wall Street Analyst Tiago Fauth

Analyst best performing recommendations are on HGEN (HUMANIGEN).
The best stock recommendation documented was for HGEN (HUMANIGEN) at 7/13/2022. The price target of $0.5 was fulfilled within 2 days with a profit of $0.11 (18.03%) receiving and performance score of 90.16.

Average potential price target upside

of $50.22 (20.39%) on UTHR (UNITED THERAPEUTICS).
of $22.74 (8.9%) on ARGX (ARGENX NV ADR).
of $44.93 (23.57%) on AMGN (AMGEN).

ABCL Abcellera Biologics APLS Apellis Pharmaceuticals ASND Ascendis Pharma AS BCAB Bioatla IFRX InflaRx N.V. IMVT Immunovant KURA Kura Oncology ME 23Andme Holding Co UTHR United Therapeutics ALXO Alx Oncology Holdings ABSI Absci Corp AMGN Amgen ARGX argenx NV ADR ARNA Arena Pharmaceuticals BMRN Biomarin Pharmaceutical HGEN Humanigen ICPT Intercept Pharmaceuticals RARE Ultragenyx RXDX Prometheus Biosciences SPRB Spruce Biosciences EDIT Editas Medicine VTYX Ventyx Biosciences FMTX Forma Therapeutics Holdings GLTO Galecto ISEE IVERIC bio PYXS Pyxis Oncology VECT VectivBio Holding AG VRDN Viridian Therapeutics ALNY Alnylam Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Robert Wasserman (BENCHMARK)